McKesson has acquired Precision Medicine Group for $2.3 billion in an all-cash transaction. The deal, announced Monday, brings the specialty pharmaceutical services provider under the umbrella of the healthcare distribution giant, which will integrate Precision’s operations into its existing oncology and biopharma services segment.
Precision Medicine Group, founded in 2012, focuses on improving the process of bringing new drugs to market through a combination of technology, data analytics, and specialized human expertise. The company builds life science services that address fundamental shifts in healthcare, particularly around outcomes improvement and the growing complexity of targeted therapies. Its model has historically blended organic investment with targeted acquisitions of capabilities it lacked, a strategy that has allowed it to serve drug developers across the clinical and commercial lifecycle.
For McKesson, the acquisition is a direct expansion of its higher-margin services business, which already includes distribution and practice management for community oncology clinics. Precision’s data-driven approach to clinical development and regulatory support will complement McKesson’s existing offerings, allowing the combined entity to provide a more seamless pipeline from drug discovery to patient access. The deal also strengthens McKesson’s position in the rapidly growing precision medicine sector, where pharmaceutical companies increasingly demand specialized support for biomarker-driven therapies.
The transaction is expected to close in the first half of the next fiscal year, subject to regulatory approvals. McKesson has stated that Precision’s leadership team will remain in place to ensure continuity for its clients. Once integrated, the combined operation will offer pharmaceutical partners a broader suite of services, from early-stage trial design to real-world evidence generation, while McKesson leverages its scale to expand Precision’s reach into new therapeutic areas. The acquisition marks a notable consolidation in the life science services market, where scale and data capabilities are becoming decisive competitive factors.